Glaucoma Supportive Care Protocol

Glaucoma is a group of eye conditions that damage the optic nerve, usually due to elevated intraocular pressure (IOP). It's a leading cause of irreversible blindness worldwide. The most common types are open-angle glaucoma (develops slowly, often without symptoms until significant vision loss) and angle-closure glaucoma (can be acute emergency). Vision loss from glaucoma cannot be recovered - the goal is preventing further damage.

CRITICAL: Glaucoma requires ongoing medical management. The primary treatment is lowering intraocular pressure through eye drops, laser treatment, or surgery. Regular eye exams with pressure checks and visual field testing are essential to monitor progression. Never stop or change your glaucoma medications without consulting your ophthalmologist. These supplements may provide additional support for optic nerve health but DO NOT replace IOP-lowering treatment. Acute angle-closure glaucoma is an emergency requiring immediate treatment.

* Citicoline (CDP-Choline) has the strongest evidence among glaucoma supplements. It has neuroprotective effects on retinal ganglion cells - the cells that die in glaucoma. Clinical trials show it may help slow visual field deterioration when added to standard IOP-lowering treatment.

* Omega-3 Fatty Acids may improve ocular blood flow and have anti-inflammatory and neuroprotective effects that support retinal health.

* Ginkgo Biloba may improve blood flow to the optic nerve and has antioxidant and neuroprotective properties. Some studies show benefit for visual field progression.

* Vitamin C is an antioxidant that may have a modest IOP-lowering effect, though this is likely not clinically significant for glaucoma treatment.

* Coenzyme Q10 supports mitochondrial function in retinal ganglion cells and may protect against oxidative damage.

* Alpha-Lipoic Acid is an antioxidant that may provide neuroprotection to the optic nerve.

* Bilberry Extract contains anthocyanins that support retinal microcirculation and eye health.

* Magnesium may improve blood flow to the optic nerve through vasodilation.

* B Vitamins - elevated homocysteine is associated with glaucoma risk; B12 and folate help lower homocysteine.

Expected timeline: Citicoline effects on visual function may be seen over months of consistent use. Glaucoma management is lifelong, with the focus on preventing further vision loss.

Clinical Perspective

Glaucoma: optic neuropathy with characteristic nerve damage and visual field loss. Types: primary open-angle (POAG, most common), angle-closure, normal-tension, secondary. Risk factors: elevated IOP (primary modifiable risk factor), age, family history, African/Hispanic ancestry, myopia, thin cornea. Diagnosis: optic disc exam, visual field testing, IOP measurement, gonioscopy, OCT. Progression: peripheral vision loss progressing to tunnel vision, blindness if untreated.

CRITICAL: Standard treatment targets IOP reduction - only proven method to slow progression. First-line: prostaglandin analogs (latanoprost, bimatoprost). Second-line: beta-blockers, alpha-agonists, carbonic anhydrase inhibitors, rho kinase inhibitors. Laser: SLT for open-angle, peripheral iridotomy for angle-closure. Surgery: trabeculectomy, tube shunts, MIGS. Target IOP varies by severity - typically 25-50% reduction. Regular monitoring essential. Supplements are ADJUNCTIVE neuroprotection - do not replace IOP-lowering treatment.

* Citicoline (B-grade): Neuroprotection; supports phospholipid synthesis. Systematic review: beneficial effects in glaucoma (PMID: 23440782). Clinical trial: improved visual function (PMID: 26591519). 500-1000mg daily. Oral or intramuscular.

* Omega-3 Fatty Acids (C-grade): Anti-inflammatory; may improve ocular perfusion. Review: potential benefits (PMID: 27116214). 2-3g EPA+DHA daily.

* Ginkgo Biloba (C-grade): Improves microcirculation; antioxidant. Systematic review: possible benefit for visual field (PMID: 23512538). 120-240mg standardized extract daily. May interact with blood thinners.

* Vitamin C (C-grade): Antioxidant; modest IOP effects. Clinical study: transient IOP reduction (PMID: 9517812). 500-1000mg daily.

* CoQ10 (C-grade): Mitochondrial support. Review: neuroprotective potential in glaucoma (PMID: 24232996). 100-200mg daily.

* Alpha-Lipoic Acid (C-grade): Antioxidant. Pilot study: visual function support (PMID: 22182233). 300-600mg daily.

* Bilberry (C-grade): Anthocyanins; retinal support. Review: eye health benefits (PMID: 24438481). 160-320mg daily.

* Magnesium (C-grade): Vasodilation; may improve ocular blood flow. Study: visual field effects (PMID: 8714442). 300-400mg daily.

* B12/Folate (C-grade): Homocysteine lowering. Meta-analysis: hyperhomocysteinemia associated with glaucoma (PMID: 26151393). B12 1000mcg, folate 400-800mcg daily.

Biomarker targets: IOP (target depends on baseline damage), visual field stability, RNFL thickness on OCT, optic disc appearance.

Protocol notes: Adherence to eye drops critical - poor compliance common cause of progression. Simplify regimen when possible. SLT can reduce drop burden. Regular follow-up: IOP, visual fields, OCT at least annually (more frequent if unstable). Screen family members - strong genetic component. Avoid high caffeine intake (transient IOP spike). Stay well-hydrated. Exercise associated with lower IOP (avoid inversion exercises, head-down positions). Sleep position: avoid sleeping face-down. Yoga inversions controversial. Tight neckties, wind instruments may increase IOP. Acute angle-closure: emergency - severe eye pain, nausea, halos around lights - requires immediate treatment. Normal-tension glaucoma: IOP in normal range but optic nerve damage - may need aggressive lowering, neuroprotection especially relevant. Watch for supplement-drug interactions: ginkgo with anticoagulants. Some supplements may affect IOP measurements. Marijuana/cannabis: transiently lowers IOP but short duration, side effects make it impractical for treatment.

View All Protocols